Enlivex Ltd
NASDAQ:ENLV
Enlivex Ltd
NASDAQ:ENLV
Price:
2.54
USD
-2.68%
Market Closed
Market Cap:
$42.7m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Enlivex Ltd
NASDAQ:ENLV
|
IL |
|
Konared Corp
OTC:KRED
|
US |
|
Eurazeo SE
PAR:RF
|
FR |
|
NRJ Group SA
F:NR8
|
FR |
|
A
|
Atlanta Poland SA
WSE:ATP
|
PL |
|
Asia Sejahtera Mina Tbk PT
IDX:AGAR
|
ID |
|
Geberit AG
F:GBRF
|
CH |
|
J
|
Jinko Power Technology Co Ltd
SSE:601778
|
CN |
|
F
|
Fresenius SE & Co KGaA
XHAN:FRE
|
DE |
|
W
|
WLS Holdings Ltd
HKEX:8021
|
HK |
|
I
|
Interarch Building Solutions Ltd
NSE:INTERARCH
|
IN |
|
Industria de Diseno Textil SA
F:IXD1
|
ES |
|
L
|
Linde PLC
XETRA:LIN
|
UK |
|
S
|
Surteco Group SE
XMUN:SUR
|
DE |
|
K
|
KB No.26 Special Purpose Acquisition Co
KOSDAQ:458320
|
KR |
|
C
|
Combined Motor Holdings Ltd
JSE:CMH
|
ZA |
|
Aerofoam Metals Inc
OTC:AFML
|
US |
Intrinsic Value
Not Available for ENLV
There is not enough data to reliably calculate the intrinsic value for Enlivex Ltd.
Do our valuations actually work? See backtest results .
Alternatives to ENLV
Fundamental Analysis
What Enlivex Does
Enlivex Therapeutics is a clinical-stage biotechnology company that develops cell-based therapies for severe inflammatory diseases. Its main program is built around a treatment called Allocetra, which uses immune cells to help reset an overactive immune response. The company is trying to turn this approach into medicines for conditions where the body’s own inflammation becomes harmful, such as sepsis and other acute disorders.
- Headquarters
- Israel IL
- Employees
- 34
- IPO date
- Jul 30, 2014
Financials
Revenue & Expenses Breakdown
Enlivex Ltd
Enlivex Ltd
Efficiency
Earnings Waterfall
Enlivex Ltd
Enlivex Ltd
